Concepedia

Author

David Walde

Ontario Institute for Cancer Research

Also Known As

D Walde, D. Walde, David Walde

28

Publications

7.7K

Citations

19

H-Index

27

Concepts

All Affiliations

Ontario Institute for Cancer ResearchEssar Steel Algoma (Canada)Hôtel-Dieu de MontréalOttawa HospitalBC Cancer Agency
DW

About

David Walde is an author at Ontario Institute for Cancer Research specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

765

2

Health Sciences

1

1

243

3

Diabetes

1

1

51

4

Emergency Medicine

1

1

51

5

Gastroenterology

1

1

51

David Walde

×

19

Publications

7.6K

Citations

19

H-Index

YearCitations

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Malcolm J. Moore, David Goldstein, John Hamm,

Journal of Clinical Oncology

2007

3.8K

Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study

Paulo M. Hoff, Rafat Ansari, Gerald Batist,

Journal of Clinical Oncology

2001

1.1K

Adjuvant Docetaxel for Node-Positive Breast Cancer

Miguel Martín, Tadeusz Pieńkowski, John R. Mackey,

New England Journal of Medicine

2005

950

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Malcolm J. Moore, David Goldstein, John Hamm,

Journal of Clinical Oncology

2023

272

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

Glenwood Goss, Andrew Arnold, Frances A. Shepherd,

Journal of Clinical Oncology

2009

243

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

John R. Mackey, Miguel Martín, Tadeusz Pieńkowski,

The Lancet Oncology

2012

221

Randomized Study of CODE Versus Alternating CAV/EP for Extensive-Stage Small-Cell Lung Cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group

Nevin Murray, Robert B. Livingston, Frances A. Shepherd,

Journal of Clinical Oncology

1999

125

Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.

Jean Latreille, Joseph L. Pater, D. Johnston,

Journal of Clinical Oncology

1998

117

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

W. Lofters, Joseph L. Pater, Benny Zee,

Journal of Clinical Oncology

1997

102

Tetrodotoxin for Moderate to Severe Cancer Pain: A Randomized, Double Blind, Parallel Design Multicenter Study

Neil A. Hagen, Patrick du Souich, Bernard Lapointe,

Journal of Pain and Symptom Management

2008

95

Page 1